{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:56:32Z","timestamp":1793372192289,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/82\/46"],"award-info":[{"award-number":["RGP2\/82\/46"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cyto.2025.156983","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:21:47Z","timestamp":1751379707000},"page":"156983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["GDF15 upregulation in Parkinson's disease: Compensatory mechanisms and causal insights"],"prefix":"10.1016","volume":"193","author":[{"given":"Sultan M.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-Kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.156983_bb0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson's disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA - Journal of the American Medical Association"},{"key":"10.1016\/j.cyto.2025.156983_bb0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biom11040612","article-title":"Review treatment options for motor and non-motor symptoms of parkinson's disease","volume":"11","author":"Church","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2025.156983_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236820","article-title":"The efficacy of dance for improving motor impairments, non-motor symptoms, and quality of life in parkinson's disease: a systematic review and meta-analysis","volume":"15","author":"Carapellotti","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.156983_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.freeradbiomed.2019.06.024","article-title":"Interactions between iron and \u03b1-synuclein pathology in Parkinson's disease","volume":"141","author":"Chen","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/WNP.0000000000000604","article-title":"The Vagus and glossopharyngeal nerves in two autonomic disorders","volume":"36","author":"Norcliffe-Kaufmann","year":"2019","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.cyto.2025.156983_bb0035","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.156983_bb0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in Early Parkinson's Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson's disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.cyto.2025.156983_bb0050","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/ene.13919","article-title":"Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease","volume":"26","author":"Durcan","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0055","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.parkreldis.2017.07.023","article-title":"Biomarkers for cognitive dysfunction in Parkinson\u2019s disease","volume":"46","author":"Kalia","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.cyto.2025.156983_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.05.036","article-title":"Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model","volume":"75","author":"Yang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2016.09.050","article-title":"Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease","volume":"370","author":"Campolo","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000477349","article-title":"Serum growth differentiation factor 15 in Parkinson disease","volume":"17","author":"Yao","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0075","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u03b2 superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.156983_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187349","article-title":"TGF-\u03b2 contamination of purified recombinant GDF15","volume":"12","author":"Olsen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.156983_bb0085","article-title":"The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not?","volume":"12","author":"Babalghith","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cyto.2025.156983_bb0090","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1523\/JNEUROSCI.20-23-08597.2000","article-title":"Growth\/differentiation factor-15\/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo","volume":"20","author":"Strelau","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fphys.2018.01712","article-title":"GDF15 and growth control","volume":"9","author":"Emmerson","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cyto.2025.156983_bb0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tem.2018.05.002","article-title":"Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond","volume":"29","author":"Mullican","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2025.156983_bb0105","doi-asserted-by":"crossref","first-page":"13640","DOI":"10.1523\/JNEUROSCI.1133-09.2009","article-title":"Progressive postnatal motoneuron loss in mice lacking GDF-15","volume":"29","author":"Strelau","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cyto.2025.156983_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2021.10705","article-title":"Emerging roles of growth differentiation factor-15 in brain disorders (review)","volume":"22","author":"Jiang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0120","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2017.01.025","article-title":"Gut-brain cross-talk in metabolic control","volume":"168","author":"Clemmensen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2025.156983_bb0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1471-4159.2005.03372.x","article-title":"Identification, expression and functional characterization of the GRAL gene","volume":"95","author":"Li","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cyto.2025.156983_bb0130","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3390\/cells10112990","article-title":"The role of gdf15 as a myomitokine","volume":"10","author":"Johann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2025.156983_bb0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.2354","article-title":"GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice","volume":"17","author":"Kempf","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2016-01-696617","article-title":"GDF-15 inhibits integrin activation and mouse neutrophil recruitment through the ALK-5\/TGF-\u03b2RII heterodimer","volume":"128","author":"Artz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.156983_bb0145","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.tem.2020.10.004","article-title":"Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets","volume":"31","author":"Rochette","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2025.156983_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129834","article-title":"GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH","volume":"1865","author":"Kim","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.cyto.2025.156983_bb0155","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11357-020-00287-w","article-title":"Disease-specific plasma levels of mitokines FGF21, GDF15, and humanin in type II diabetes and Alzheimer's disease in comparison with healthy aging","volume":"43","author":"Conte","year":"2021","journal-title":"Geroscience"},{"key":"10.1016\/j.cyto.2025.156983_bb0160","first-page":"74","article-title":"The role of hepcidin, GDF15, and mitoferrin-1 in iron metabolism of polycythemia vera and essential thrombocytosis patients, Turk","volume":"49","author":"Albayrak","year":"2019","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0165","first-page":"184","article-title":"Growth differentiation factor 15 in erythroid health and disease","volume":"17","author":"Tanno","year":"2010","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.cyto.2025.156983_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109501","article-title":"GDF15 mediates the metabolic effects of PPAR\u03b2\/\u03b4 by activating AMPK","volume":"36","author":"Aguilar-Recarte","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cyto.2025.156983_bb0175","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jad.2019.09.037","article-title":"The association between serum growth differentiation factor-15 and 3-month depression after acute ischemic stroke","volume":"260","author":"Lu","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cyto.2025.156983_bb0180","article-title":"Growth differentiation factor 15 is associated with Alzheimer's disease risk","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.cyto.2025.156983_bb0185","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.031","article-title":"The Association of Growth Differentiation Factor-15 gene polymorphisms with growth differentiation Factor-15 serum levels and risk of ischemic stroke","volume":"26","author":"Xiang","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00441-010-1090-5","article-title":"Regulation of GDF-15, a distant TGF-\u03b2 superfamily member, in a mouse model of cerebral ischemia","volume":"343","author":"Schindowski","year":"2011","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0195","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0140-6736(02)09093-1","article-title":"Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study","volume":"359","author":"Brown","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.156983_bb0200","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/00207454.2019.1660327","article-title":"Association of serum growth differentiation factor 15 level with acute ischemic stroke in a Chinese population","volume":"129","author":"Dong","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fneur.2019.00611","article-title":"Growth differentiation Factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy","volume":"10","author":"Breni\u00e8re","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0210","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1074\/jbc.M210037200","article-title":"Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways","volume":"278","author":"Subramaniam","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2025.156983_bb0215","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1089\/scd.2014.0487","article-title":"GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model","volume":"24","author":"Kim","year":"2015","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.cyto.2025.156983_bb0220","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/acel.12116","article-title":"Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney memory and aging study","volume":"12","author":"Fuchs","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.cyto.2025.156983_bb0225","article-title":"The relationship of serum macrophage inhibitory cytokine - 1 levels with gray matter volumes in community-dwelling older individuals","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.156983_bb0230","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1242\/dev.096131","article-title":"Growth\/differentiation factor 15 promotes EGFR signalling, and regulates proliferation and migration in the hippocampus of neonatal and young adult mice","volume":"141","author":"Carrillo-Garc\u00eda","year":"2014","journal-title":"Development (Cambridge)"},{"key":"10.1016\/j.cyto.2025.156983_bb0235","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neuron.2017.10.005","article-title":"Molecular neuroscience in the 21st century: a personal perspective","volume":"96","author":"S\u00fcdhof","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.cyto.2025.156983_bb0240","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI30284","article-title":"Dysfunction of TGF-beta signaling in Alzheimer's disease","volume":"116","author":"Das","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2025.156983_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111228","article-title":"GDF15 as a biomarker of ageing","volume":"146","author":"Liu","year":"2021","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.cyto.2025.156983_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ebiom.2019.02.021","article-title":"Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: a mendelian randomization study","volume":"41","author":"Cheung","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cyto.2025.156983_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116429","article-title":"GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis","volume":"405","author":"Nohara","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0260","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.nmd.2017.06.102","article-title":"GDF-15 expression in mitochondrial and other neurological diseases","volume":"27","author":"Ishii","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cyto.2025.156983_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149349","article-title":"GDF15\/MIC1 and MMP9 cerebrospinal fluid levels in Parkinson's disease and Lewy body dementia","volume":"11","author":"Maetzler","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.156983_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2015.12.016","article-title":"Growth\/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease","volume":"88","author":"Machado","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00441-016-2406-x","article-title":"Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice","volume":"365","author":"Machado","year":"2016","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0280","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.carpath.2012.02.003","article-title":"Increased expression of the TGF-b superfamily cytokine MIC-1\/GDF15 protects ApoE\u2212\/\u2212 mice from the development of atherosclerosis","volume":"21","author":"Johnen","year":"2012","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.cyto.2025.156983_bb0285","first-page":"197","article-title":"Growth\/differentiation factor-15 (GDF-15), a novel member of the TGF-\u03b2 superfamily, promotes survival of lesioned mesencephalic dopaminergic neurons in vitro and in vivo and is induced in neurons following cortical lesioning, journal of neural transmission","author":"Strelau","year":"2003","journal-title":"Supplement"},{"key":"10.1016\/j.cyto.2025.156983_bb0290","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/glia.23627","article-title":"Subregional differences in astrocytes underlie selective neurodegeneration or protection in Parkinson's disease models in culture","volume":"67","author":"Kostuk","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.cyto.2025.156983_bb0295","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1002\/jcb.28339","article-title":"GDF-15 promotes mitochondrial function and proliferation in neuronal HT22 cells","volume":"120","author":"Liu","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cyto.2025.156983_bb0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/CPJ.0000000000000702","article-title":"Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease","volume":"10","author":"Davis","year":"2020","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.cyto.2025.156983_bb0305","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/eurheartj\/eht152","article-title":"Neurohormonal and clinical sex differences in heart failure","volume":"34","author":"Meyer","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cyto.2025.156983_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116616","article-title":"Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease","volume":"409","author":"Miyaue","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0315","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/glia.23627","article-title":"Diagnostic utility of GDF15 in neurodegenerative diseases: a systematic review and met Kostuk EW, Cai J, Iacovitti L. Subregional differences in astrocytes underlie selective neurodegeneration or protection in Parkinson's disease models in culture","volume":"67","author":"Xue","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.cyto.2025.156983_bb0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrn1868","article-title":"Expanding insights of mitochondrial dysfunction in Parkinson's disease","volume":"7","author":"Abou-Sleiman","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.cyto.2025.156983_bb0325","first-page":"29","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"2010","author":"Winklhofer","year":"1802","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.cyto.2025.156983_bb0330","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2741\/2119","article-title":"Mitochondrial toxins and neurodegenerative diseases","volume":"12","author":"Ayala","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.10.061","article-title":"Complex I deficiency in Parkinson's disease frontal cortex","volume":"1189","author":"Parker","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0340","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1073858415574600","article-title":"The Parkinson disease mitochondrial hypothesis: where are we at?","volume":"22","author":"Franco-Iborra","year":"2016","journal-title":"Neuroscientist"},{"key":"10.1016\/j.cyto.2025.156983_bb0345","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1523\/JNEUROSCI.22-16-07006.2002","article-title":"An in vitro model of Parkinson\u2019s disease: linking mitochondrial impairment to altered \u03b1-synuclein metabolism and oxidative damage","volume":"22","author":"Sherer","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10020352","article-title":"Dysregulation of PGC-1\u03b1-dependent transcriptional programs in neurological and developmental disorders: therapeutic challenges and opportunities","volume":"10","author":"McMeekin","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2025.156983_bb0355","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pneurobio.2011.10.004","article-title":"PGC-1\u03b1 at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond","volume":"97","author":"Tsunemi","year":"2012","journal-title":"Prog. Neurobiol."},{"issue":"1842","key":"10.1016\/j.cyto.2025.156983_bb0360","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbadis.2014.02.010","article-title":"Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease","volume":"7","author":"Ferretta","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"issue":"1812","key":"10.1016\/j.cyto.2025.156983_bb0365","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bbadis.2010.12.022","article-title":"Mitochondrial defect and PGC-1\u03b1 dysfunction in parkin-associated familial Parkinson's disease","volume":"8","author":"Pacelli","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.cyto.2025.156983_bb0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1371\/journal.pone.0048925","article-title":"Pgc-1\u03b1 overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf","volume":"7","author":"Clark","year":"2012","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2025.156983_bb0375","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ggi.12724","article-title":"Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders","volume":"16","author":"Fujita","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.cyto.2025.156983_bb0380","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ana.24506","article-title":"Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders","volume":"78","author":"Yatsuga","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0385","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.mito.2007.07.002","article-title":"Therapeutic potential of pyruvate therapy for mitochondrial diseases","volume":"7","author":"Tanaka","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.cyto.2025.156983_bb0390","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1373\/clinchem.2012.201210","article-title":"Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals","volume":"59","author":"Eggers","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cyto.2025.156983_bb0395","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1007\/s12035-016-0283-7","article-title":"Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases","volume":"54","author":"Ji","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.cyto.2025.156983_bb0400","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrm3877","article-title":"Mitochondrial dynamics and inheritance during cell division, development and disease","volume":"15","author":"Mishra","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cyto.2025.156983_bb0405","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3892\/mmr.2014.2563","article-title":"Inflammatory response in Parkinson's disease","volume":"10","author":"Yan","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cyto.2025.156983_bb0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12017-014-8294-x","article-title":"Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease","volume":"16","author":"Gaki","year":"2014","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/mds.28075","article-title":"Ten unsolved questions about neuroinflammation in Parkinson's disease","volume":"36","author":"Hirsch","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cyto.2025.156983_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-020-01083-5","article-title":"Neuroinflammation and protein pathology in Parkinson's disease dementia","volume":"8","author":"Kouli","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.cyto.2025.156983_bb0425","article-title":"Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer","volume":"18","author":"Batiha","year":"2022","journal-title":"Sci Afr"},{"key":"10.1016\/j.cyto.2025.156983_bb0430","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0435","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2025.156983_bb0440","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mds.27874","article-title":"Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease","volume":"35","author":"Haque","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cyto.2025.156983_bb0445","article-title":"Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats","volume":"146","author":"Abdelaziz","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114692","article-title":"Alpha-synuclein drives NURR1 and NLRP3 inflammasome dysregulation in Parkinson's disease: from pathogenesis to potential therapeutic strategies","volume":"156","author":"Abdelaziz","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0455","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1186\/s12974-019-1670-6","article-title":"Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson's disease","volume":"17","author":"Fan","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2025.156983_bb0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-017-1788-5","article-title":"Parkinson's disease: experimental models and reality","volume":"135","author":"Jiang","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cyto.2025.156983_bb0465","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12974-018-1236-z","article-title":"Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP\/p mouse model of Parkinson's disease","volume":"15","author":"Qiao","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2025.156983_bb0470","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.4049\/jimmunol.1801416","article-title":"Dysregulation of inflammasome priming and activation by MicroRNAs in human immune-mediated diseases","volume":"202","author":"Boxberger","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.156983_bb0475","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated \u03b1-synuclein, an inflammatory response in Synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2025.156983_bb0485","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharmthera.2019.02.008","article-title":"Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases","volume":"198","author":"Baek","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2025.156983_bb0490","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.09.040","article-title":"NLRP3 Inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis","volume":"158","author":"Sendler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2025.156983_bb0495","first-page":"1","article-title":"GDF11 alleviates neointimal hyperplasia in a rat model of artery injury by regulating endothelial NLRP3 inflammasome activation and rapid re-endothelialization","volume":"20","author":"Li","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0500","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41419-020-03120-6","article-title":"GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0505","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/mt.2016.160","article-title":"GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in apolipoprotein E-null mice","volume":"24","author":"Mei","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cyto.2025.156983_bb0510","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1007\/s11033-021-06770-7","article-title":"Niclosamide for Covid-19: bridging the gap","volume":"48","author":"Al-kuraishy","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cyto.2025.156983_bb0515","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2021-0099","article-title":"Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19","volume":"8","author":"Al-Kuraishy","year":"2022","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.cyto.2025.156983_bb0520","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clnesp.2021.12.030","article-title":"El-Saber Batiha, the possible role of ursolic acid in Covid-19: a real game changer","volume":"47","author":"Al-kuraishy","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.cyto.2025.156983_bb0525","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10787-022-00988-y","article-title":"High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons","volume":"30","author":"Al-kuraishy","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2025.156983_bb0530","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12640-019-00147-2","article-title":"NF-\u03baB-mediated neuroinflammation in Parkinson's disease and potential therapeutic effect of polyphenols","volume":"37","author":"Sen Singh","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0535","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1097\/00001756-199709080-00009","article-title":"Nuclear translocation of NF-\u03baB in cholinergic neurons of patients with Alzheimer's disease","volume":"8","author":"Boissi\u00e8re","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.cyto.2025.156983_bb0540","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.0704908104","article-title":"Selective inhibition of NF-\u03baB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease","volume":"104","author":"Ghosh","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.156983_bb0545","article-title":"Transcriptional factor NF-\u03bab as a target for therapy in Parkinson's disease","volume":"2011","author":"Flood","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0550","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1111\/ejn.15242","article-title":"Nuclear factor-kappa B (NF-\u03baB) in pathophysiology of Parkinson disease: diverse patterns and mechanisms contributing to neurodegeneration","volume":"54","author":"Dolatshahi","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0555","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neurobiolaging.2014.07.043","article-title":"Correlation between decreased CSF \u03b1-synuclein and A\u03b21-42 in Parkinson disease","volume":"36","author":"Buddhala","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cyto.2025.156983_bb0560","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0565","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.258","article-title":"A\u03b21-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-\u03baB signaling","volume":"5","author":"Park","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0570","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1128\/MCB.19.8.5785","article-title":"NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1","volume":"19","author":"Guttridge","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cyto.2025.156983_bb0575","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/cam4.3850","article-title":"Growth and differentiation factor 15 and NF-\u03baB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection","volume":"10","author":"Rybicki","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.cyto.2025.156983_bb0580","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1172\/JCI91561","article-title":"NF-\u03baB regulates GDF-15 to suppress macrophage surveillance during early tumor development","volume":"127","author":"Ratnam","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2025.156983_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.002550","article-title":"Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury","volume":"1","author":"Bonaterra","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.cyto.2025.156983_bb0590","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation Factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156983_bb0595","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","article-title":"GDF15 is an inflammation-induced central mediator of tissue tolerance","volume":"178","author":"Luan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2025.156983_bb0600","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","article-title":"Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss","volume":"1","author":"Day","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cyto.2025.156983_bb0605","first-page":"1","article-title":"Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells","volume":"11","author":"Yang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.156983_bb0610","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7208429","article-title":"The effect of diabetes medication on cognitive function: evidence from the PATH through life study","volume":"2016","author":"Herath","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cyto.2025.156983_bb0615","first-page":"A19","article-title":"The effect of metformin exposure on neurodegenerative disease among elder adult veterans with diabetes mellitus","volume":"65","author":"Shi","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2025.156983_bb0620","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.cyto.2025.156983_bb0625","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2025.156983_bb0630","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.cyto.2025.156983_bb0635","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/ejn.12556","article-title":"Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke","volume":"39","author":"Venna","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0640","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neuropharm.2015.07.023","article-title":"Antidiabetic drugs restore abnormal transport of amyloid-\u03b2 across the blood-brain barrier and memory impairment in db\/db mice","volume":"101","author":"Chen","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cyto.2025.156983_bb0645","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2016.05.148","article-title":"Metformin preconditioning provide neuroprotection through enhancement of autophagy and suppression of inflammation and apoptosis after spinal cord injury","volume":"477","author":"Wang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2025.156983_bb0650","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1161\/STROKEAHA.110.589697","article-title":"Effects of metformin in experimental stroke","volume":"41","author":"Li","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.cyto.2025.156983_bb0655","doi-asserted-by":"crossref","first-page":"48603","DOI":"10.18632\/oncotarget.18122","article-title":"Activation of the ATF2\/CREB-PGC-1\u03b1 pathway by metformin leads to dopaminergic neuroprotection","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cyto.2025.156983_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104593","article-title":"Emerging neuroprotective effect of metformin in Parkinson's disease: a molecular crosstalk","volume":"152","author":"Paudel","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0665","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.cyto.2025.156983_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728315","article-title":"Deciphering the roles of metformin in Alzheimer's disease: a snapshot","volume":"12","author":"Liao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111349","article-title":"Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson's disease: role of glutamate modulators","volume":"225","author":"Almohmadi","year":"2025","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.cyto.2025.156983_bb0680","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cyto.2025.156983_bb0685","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2011.01.022","article-title":"Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes","volume":"220","author":"Bhutada","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0690","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/brain\/awu369","article-title":"Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11 C-donepezil PET","volume":"138","author":"Gjerl\u00f8ff","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.cyto.2025.156983_bb0695","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and parkinson's disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.cyto.2025.156983_bb0700","first-page":"543","article-title":"Growth differentiation factor-15\/macrophage inhibitory cytokine-1 induction after kidney and lung injury","volume":"23","author":"Zimmers","year":"2005","journal-title":"Shock"},{"key":"10.1016\/j.cyto.2025.156983_bb0705","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/biomedicines9080918","article-title":"Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in parkinson's disease","volume":"9","author":"Kung","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cyto.2025.156983_bb0710","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnagi.2020.00103","article-title":"Resveratrol derivatives as potential treatments for Alzheimer's and Parkinson's disease","volume":"12","author":"Arbo","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644219","article-title":"Resveratrol in rodent models of Parkinson's disease: a systematic review of experimental studies","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0720","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Others, non-steroidal anti-inflammatory drugs in Parkinson's disease","volume":"205","author":"Esposito","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.cyto.2025.156983_bb0725","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jocn.2007.02.095","article-title":"Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study","volume":"15","author":"Etminan","year":"2008","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.cyto.2025.156983_bb0730","article-title":"Do PPAR-gamma agonists have a future in parkinson's disease therapy?","volume":"2011","author":"Carta","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.cyto.2025.156983_bb0735","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms222312740","article-title":"Glitazone treatment rescues phenotypic deficits in a fly model of Gaucher\/Parkinson's disease","volume":"22","author":"Shola-Dare","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0740","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s10072-020-04494-3","article-title":"Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence","volume":"41","author":"Hussain","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.cyto.2025.156983_bb0745","article-title":"Genistein: a focus on several neurodegenerative diseases","volume":"46","author":"Li","year":"2022","journal-title":"J. Food Biochem."},{"key":"10.1016\/j.cyto.2025.156983_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109986","article-title":"Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: correlation between Nrf2 and HMGB1\/TLR4\/PI3K\/Akt\/mTOR signaling","volume":"117","author":"El-Sayed","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.156983_bb0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neures.2007.10.005","article-title":"Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease","volume":"60","author":"Liu","year":"2008","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.cyto.2025.156983_bb0760","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00001756-200502280-00013","article-title":"Genistein protects dopaminergic neurons by inhibiting microglial activation","volume":"16","author":"Wang","year":"2005","journal-title":"Neuroreport"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:51:29Z","timestamp":1752601889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":152,"alternative-id":["S1043466625001309"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156983","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GDF15 upregulation in Parkinson's disease: Compensatory mechanisms and causal insights","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156983"}}